Effect of lamivudine treatment on plasma levels of transforming growth factor &beta;1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

288

HTML

2290

Figures (1-4)

193

Tables (1-5)

205

Sum=2976

Sep 15, 2004 (publication date) through Nov 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Sep 15, 2004; 10(18): 2661-2665
Published online Sep 15, 2004. doi: 10.3748/wjg.v10.i18.2661

Table 1 Plasma concentrations of TGF-β₁, TIMP-1 and MMP-1 during treatment with lamivudine (mean ± SE)

	Normal values	Time since treatment beginning (wk)
	Normal values	0	24	48	72
TGF-β₁ (ng/mL)	18.3 ± 1.6	29.6 ± 2.2¹	22.6 ± 1.2²	21.9 ± 1.5²	24.1 ± 2.4
TIMP-1 (ng/mL)	1102.0 ± 67	1578.0 ± 93¹	1235.0 ± 67²	927.0 ± 50²	1215.0 ± 98²
MMP-1 (ng/mL)	11.9 ± 0.9	6.7 ± 0.7¹	8.3 ± 0.5¹	9.6 ± 0.5¹	9.7 ± 0.7²

Statistical significance in comparison with

¹normal and

²baseline values.

Citation: Flisiak R, Al-Kadasi H, Jaroszewicz J, Prokopowicz D, Flisiak I. Effect of lamivudine treatment on plasma levels of transforming growth factor β₁, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B. World J Gastroenterol 2004; 10(18): 2661-2665
URL: https://www.wjgnet.com/1007-9327/full/v10/i18/2661.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i18.2661